Table 3.
Pooled and subgroup analyses of data synthesis of cancer-specific survival and recurrence-free survival for this meta-analysis
| Categories | Study (case) | Model | HR (95% CI) | Z | PZ | Heterogeneity | Pm | |
|---|---|---|---|---|---|---|---|---|
| I2 | Ph | |||||||
| Cancer-specific survival (CSS) | 8 (5640) | Fixed | 2.07 (1.74–2.46) | 8.25 | <0.001 | 38.1% | 0.126 | |
| Study population | 0.893 | |||||||
| Asian | 6 (5193) | Fixed | 2.12 (1.76–2.56) | 7.86 | <0.001 | 0.0% | 0.605 | |
| Caucasian | 2 (447) | Random | 2.60 (0.61–11.09) | 1.29 | 0.198 | 86.2% | 0.007 | |
| Cancer type | 0.574 | |||||||
| RCC | 4 (3741) | Fixed | 1.78 (1.42–2.22) | 5.01 | <0.001 | 18.0% | 0.301 | |
| Bladder cancer | 2 (267) | Fixed | 3.78 (2.02–7.04) | 4.17 | <0.001 | 24.4% | 0.250 | |
| UTUC | 2 (1632) | Fixed | 2.38 (1.76–3.22) | 5.63 | <0.001 | 0.0% | 0.697 | |
| Clinical stage | 0.536 | |||||||
| I-IV | 2 (1347) | Random | 1.85 (1.05–3.48) | 2.10 | 0.046 | 75.0% | 0.045 | |
| T1-T4 | 4 (3815) | Fixed | 2.55 (1.90–3.45) | 6.30 | <0.001 | 9.5% | 0.345 | |
| IV | 2 (478) | Fixed | 1.74 (1.28–2.34) | 3.53 | <0.001 | 0.0% | 0.416 | |
| Cutoff value | 0.316 | |||||||
| >1.3 | 5 (5044) | Random | 2.26 (1.63–3.15) | 4.83 | <0.001 | 53.0% | 0.074 | |
| ≤1.3 | 3 (596) | Fixed | 1.84 (1.38–2.45) | 4.16 | <0.001 | 0.0% | 0.419 | |
| Sample size | 0.199 | |||||||
| ≥200 | 5 (5255) | Fixed | 1.95 (1.62–2.36) | 6.95 | <0.001 | 33.8% | 0.196 | |
| <200 | 3 (385) | Fixed | 2.82 (1.83–4.34) | 4.69 | <0.001 | 32.1% | 0.229 | |
| Recurrence-free survival (RFS) | 5 (4751) | Random | 1.51 (1.15–1.99) | 2.95 | 0.003 | 64.2% | 0.025 | |
Note: PZ denotes P-value for statistical significance based on Z test; Ph denotes P-value for heterogeneity based on Q test; Pm denotes P-value for statistical outcome based on multivariate meta-regression analysis.
Abbreviations: RCC, renal cell carcinoma; UTUC, urinary tract urothelial carcinoma.